Operating

Other operating reconciliation adjustments

Regeneron Pharmaceuticals Other operating reconciliation adjustments increased by 7.9% to $351.70M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 48.8%, from $236.40M to $351.70M.

Analysis

StatementCash Flow Statement
SectionOperating
CategoryOther
SignalContext dependent
VolatilityStable
First reportedQ1 2013
Last reportedQ1 2026Apr 29, 2026

How to read this metric

Large or frequent adjustments may signal complex accounting or significant non-recurring operational events.

Detailed definition

This captures miscellaneous adjustments required to reconcile net income to net cash provided by operating activities th...

Peer comparison

Company-specific; varies widely based on accounting policies and business complexity.

Metric ID: intc_other_operating_reconciling_items

Historical Data

15 periods
 Q2 '21Q1 '22Q4 '22Q1 '23Q2 '23Q3 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value-$2.47B$1.13B$522.80M$549.80M$54.00M$106.50M$790.50M-$1.08B-$49.40M$345.10M$236.40M-$247.20M$158.70M$326.10M$351.70M
QoQ Change+145.6%-53.7%+5.2%-90.2%+97.2%+642.3%-236.4%+95.4%+798.6%-31.5%-204.6%+164.2%+105.5%+7.9%
YoY Change-51.3%+43.8%<-999%-146.4%-70.1%+77.1%+421.3%-5.5%+48.8%
Range-$2.47B$1.13B
CAGR-42.7%
Avg YoY Growth-197.7%
Median YoY Growth-5.5%
Current Streak3 quarters growth

Frequently Asked Questions

What is Regeneron Pharmaceuticals's other operating reconciliation adjustments?
Regeneron Pharmaceuticals (REGN) reported other operating reconciliation adjustments of $351.70M in Q1 2026.
How has Regeneron Pharmaceuticals's other operating reconciliation adjustments changed year-over-year?
Regeneron Pharmaceuticals's other operating reconciliation adjustments increased by 48.8% year-over-year, from $236.40M to $351.70M.
What does other operating reconciliation adjustments mean?
Other non-cash adjustments used to reconcile net income to operating cash flow.